Clinical Biologic Imaging and Genetic Repository (C-BIG Repository)
“It's essential that we aggregate biological materials and high-quality multi-modal patient data to advance our understanding of the molecular changes driving rare neurological diseases. With the C-BIG Repository, we are making it easier to do clinical and translational research, accelerating our ability to collect meaningful information with the goal of improving patient care."
- Jason Karamchandani
The Neuro's C-BIG Repository is a collection of biological samples, clinical information, imaging and genetic data from people with neurological disease as well as healthy control subjects.
The C-BIG Repository facilitates research into molecular biology underlying patient disease and the discovery of biomarkers to improve the diagnosis of patients, and drives tissue-based translational research that will accelerate drug development.
The Repository is supported by a robust and unique ethical framework that empowers patients by allowing them to participate indirectly in research aimed at advancing understanding of neurological diseases. It also recognizes the primacy of safeguarding the dignity and privacy of patient-participants, and respecting the rights and duties owed them through the informed consent process.
Early Drug Discovery Platform
“The Neuro’s Early Drug Discovery Platform fuels Open Science at The Neuro and beyond. We are actively engaging and working with pharma and industry partners, training the next generation of researchers, and using the platform to fill a critical gap in the drug discovery pathway."
- Edward Fon
The Neuro’s Early Drug Discovery Platform leverages breakthroughs in induced pluripotent stem cell (iPSC) technology to build industry-standard assays and discover new and improved treatments for patients and their families. Anchored on strategic partnerships with the Structural Genomics Consortium (SGC) and the Centre for Drug Research and Development, the platform has successfully formed agreements with high-level companies like Merck and Thermo-Fisher Scientific.
A more recent collaboration was signed with Takeda Pharmaceutical Company to test compounds developed in Takeda labs to fight ALS (Amyotrophic Lateral Sclerosis), a disease that currently has no cure.
“The Open Science revolution is dramatically changing the way we do science. Making data freely available through The Neuro’s informatics platforms means that more people are using data to test their ideas. This accelerates the process of discovery and shortens the time to develop vital treatments for people with neurological diseases."
- Alan Evans
To help researchers make their data open and access open data available elsewhere, The Neuro has made advances in neuroinformatics infrastructure. The Neuro's researchers have long been leaders in developing software and neuroinformatics infrastructure.